The role of positron emission tomography in the management of non-small cell lung cancer.
The potential use of positron emission tomography (PET) imaging in patients with non-small cell lung cancer (NSCLC) is broadly divided into 5 categories: management of solitary pulmonary nodule, mediastinal lymph node evaluation, detection of metastases, evaluation of response to chemoradiation and detection of recurrence. The purpose of this review is to discuss the current clinical applications of (18)F-fluorodeoxyglucose PET in patients with NSCLC and to discuss future applications and developments of this technology.
Behzadi
Abdollah
A
Department of Surgery, The Scarborough Hospital, Toronto, Ont. abehzadi@tsh.to
Ung
Yee
Y
Lowe
Val
V
Deschamps
Claude
C
D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18